call transcript and financial accounting and sciele pharma inc. Resources | BNET
On TV.com: THE GIRLS NEXT DOOR photos

BNET Industries

Sciele Pharma Inc. (SCRX) is in the Pharma Industry

Revenue
Dec 31 2007
$382.2M
Profit
Dec 31 2007
$45.4M
Market Cap
Oct 08 2008
$979.5M

Latest News and Analysis

  • Sciele Pharma and Plethora Solutions Announce Positive Phase III Clinical Results of PSD502 for Premature Ejaculation

    ATLANTA & LONDON -- Sciele Pharma, Inc.: * Statistically and clinically significant increase in all three co-primary endpoints * Well tolerated and devoid of systemic side effects Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Holdings PLC ("Plethora"-AIM:PLE), the specialist developer of products...

    Articles 2008-11-07

  • Sciele Pharma Announces That Addrenex Pharmaceuticals Initiates Phase II Clinical Trial of ADX415 for the Treatment of Hypertension

    ATLANTA -- Sciele Pharma, Inc., a Shionogi Company, today announced that Addrenex Pharmaceuticals, Inc. has initiated its Phase II clinical trial with ADX415 for the treatment of hypertension. This is a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study that will involve 80 patients. ADX415 is a novel, patented, centrally acting, alpha-adrenergic...

    Articles 2008-10-23

  • Shionogi and Sciele Announce Completion of Subsequent Offering Period

    ATLANTA & OSAKA, Japan -- On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the successful completion of the cash tender offer by Shionogi's indirect wholly owned subsidiary, Tall Bridge, Inc. ("Purchaser"), to acquire all outstanding shares of common stock of Sciele...

    Articles 2008-10-09

  • Shionogi Completes Acquisition of Sciele

    OSAKA, Japan & ATLANTA -- On October 9, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the completion of Shionogi's acquisition of Sciele for US$31.00 per share in cash. Shionogi completed the acquisition through a cash tender offer followed by short-form merger of the...

    Articles 2008-10-09

  • Shionogi and Sciele Announce Successful Tender Offer and Commencement of Subsequent Offering

    ATLANTA & OSAKA, Japan -- On October 6, 2008, Shionogi & Co., Ltd. ("Shionogi") and Sciele Pharma, Inc. ("Sciele") (NASDAQ: SCRX) announced the successful completion of the tender offer by Shionogi's indirect wholly owned subsidiary, Tall Bridge, Inc. ("Purchaser"), to acquire all outstanding shares of common stock of Sciele for...

    Articles 2008-10-06

  • page 1 of 1
  • Incorporated: 1992
  • CEO: Mr. Patrick P. Fourteau
  • Employees: 920

Sciele Pharma is engaged in marketing and development of prescription products focused on Cardiovascular, Diabetes, Women's Health, and Pediatric treatment. Co.'s Cardiovascular, Diabetes products treat patients with high cholesterol, hypertension, high triglycerides, unstable angina, and Type 2 Diabetes. Co.'s Women's Health products are designed to improve the health and well-being of women of all ages, as well as expectant and nursing mothers and their babies. Co.'s Pediatric product focus includes the sub-specialties of allergy and immunology, psychiatry, neurology, urology and infectious diseases. As of Dec 31 2007, Co. marketed and sold 21 products, 11 of which are actively promoted.

Key Competitors

advertisement
Industry Transcripts by Seeking Alpha
Sciele Pharma Inc. Company Info

Board of Directors

Mr. Pierre Lapalme

Chairman

Mr. Patrick P. Fourteau

Mr. Jerry N. Ellis

Dr. Jerry C. Griffin M.D.

Mr. William J. Robinson

Mr. Jon S. Saxe

Mr. Patrick J. Zenner

Contact Information

6195 Shiloh Road

Alpharetta, GA

http://www.horizonpharm.com

770 442-9707

NAICS Code

Drugs and Druggists' Sundries Merchant Wholesalers: 424210
advertisement